Yumanity's drug is a stearoyl-CoA desaturase inhibitor. Stearoyl-CoA desaturase has ben implicated in Parkinson's and cancer tumor growth. The FDA may have allowed single dose studies to continue but shut down multiple dose studies because the imbalance of to little SCD was causing problems.

SCD is overexpressed when there is an overactive PI3K/Akt/mTOR pathway. Leronlimab downregulates that pathway but wouldn't shut down SCD completely because of the activity of other CCR receptors.